A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination
with peginterferon alfa-2a (PegIFNα-2a) and ribavirin in genotype 1 hepatitis C virus
(HCV)-infected participants who relapsed after previous interferon (IFN)-based therapy in
Japan.